Published in Genes Chromosomes Cancer on July 01, 2010
Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer (2010) 2.95
miR-222 is necessary for exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell Metab (2015) 1.85
A novel computational framework for simultaneous integration of multiple types of genomic data to identify microRNA-gene regulatory modules. Bioinformatics (2011) 1.68
The role of microRNAs in ovarian cancer. Biomed Res Int (2014) 1.15
MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. World J Surg Oncol (2012) 1.12
Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. BMC Cancer (2014) 0.99
Relationship between circulating and tissue microRNAs in a murine model of breast cancer. PLoS One (2012) 0.96
Roles and mechanisms of microRNAs in pancreatic cancer. World J Surg (2011) 0.90
miR-222 is upregulated in epithelial ovarian cancer and promotes cell proliferation by downregulating P27(kip1.) Oncol Lett (2013) 0.87
Circulating MicroRNAs as Biomarkers in Health and Disease. J Clin Diagn Res (2012) 0.85
Translational application of epigenetic alterations: ovarian cancer as a model. FEBS Lett (2011) 0.83
Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer. Pancreas (2013) 0.81
Expression patterns and miRNA regulation of DNA methyltransferases in chicken primordial germ cells. PLoS One (2011) 0.80
Microarray based analysis of gene regulation by microRNA in intervertebral disc degeneration. Mol Med Rep (2015) 0.79
Impact of Nutrition on Non-Coding RNA Epigenetics in Breast and Gynecological Cancer. Front Nutr (2015) 0.77
MicroRNAs as Biomarkers in Cancer. Diagnostics (Basel) (2013) 0.77
Prognostic role of microRNA-221 in various human malignant neoplasms: a meta-analysis of 20 related studies. PLoS One (2014) 0.76
Expression Profile Analysis of miR-221 and miR-222 in Different Tissues and Head Kidney Cells of Cynoglossus semilaevis, Following Pathogen Infection. Mar Biotechnol (NY) (2015) 0.76
Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma. Expert Rev Mol Diagn (2016) 0.75
MicroRNA-595 sensitizes ovarian cancer cells to cisplatin by targeting ABCB1. Oncotarget (2016) 0.75
3,39-Diindolylmethane Ameliorates Staphylococcal Enterotoxin B–Induced Acute Lung Injury through Alterations in the Expression of MicroRNA that Target Apoptosis and Cell-Cycle Arrest in Activated T Cells. J Pharmacol Exp Ther (2016) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
MicroRNA signatures in human ovarian cancer. Cancer Res (2007) 9.45
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A (2006) 8.24
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
MicroRNA expression and function in cancer. Trends Mol Med (2006) 7.02
Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J (2007) 6.26
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79
Clustering and conservation patterns of human microRNAs. Nucleic Acids Res (2005) 4.79
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene (2008) 4.11
MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res (2008) 2.97
Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle (2007) 2.78
MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One (2008) 2.60
Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One (2009) 2.37
Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res (2003) 1.56
CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer. BMC Cancer (2008) 1.17
The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma. Int J Gynecol Pathol (2007) 1.16
Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res (1999) 1.10
Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival. Hum Pathol (2001) 1.04
The concurrent expression of p27(kip1) and cyclin D1 in epithelial ovarian tumors. Gynecol Oncol (1999) 0.93
Expression of p57kip2 and its clinical relevance in epithelial ovarian tumors. Anticancer Res (2003) 0.92
Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study. Clin Cancer Res (1999) 0.82
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
The accessible chromatin landscape of the human genome. Nature (2012) 16.86
A map of the interactome network of the metazoan C. elegans. Science (2004) 15.60
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A (2011) 10.56
Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods (2010) 6.25
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A (2010) 5.60
Therapeutic outcomes in 1000 cases of endoscopic submucosal dissection for early gastric neoplasms: Korean ESD Study Group multicenter study. Gastrointest Endosc (2009) 4.76
Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet (2007) 4.69
MicroRNA profiling: approaches and considerations. Nat Rev Genet (2012) 4.39
Functional genomic analysis of RNA interference in C. elegans. Science (2005) 4.36
Limitations and possibilities of small RNA digital gene expression profiling. Nat Methods (2009) 4.34
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 3.99
Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods (2013) 3.63
Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res (2013) 3.25
Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv1 prostate carcinoma cells. J Virol (2009) 3.16
MicroRNA discovery and profiling in human embryonic stem cells by deep sequencing of small RNA libraries. Stem Cells (2008) 3.14
Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology, and clinical follow-up. Am J Surg Pathol (2002) 2.70
Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res (2009) 2.54
Empirically controlled mapping of the Caenorhabditis elegans protein-protein interactome network. Nat Methods (2009) 2.50
HIF induces human embryonic stem cell markers in cancer cells. Cancer Res (2011) 2.46
Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One (2009) 2.37
Post-transcriptional generation of miRNA variants by multiple nucleotidyl transferases contributes to miRNA transcriptome complexity. Genome Res (2011) 2.34
Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol (2011) 2.33
The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer (2010) 2.13
The limits of reductionism in medicine: could systems biology offer an alternative? PLoS Med (2006) 2.13
Histone deacetylase inhibition elicits an evolutionarily conserved self-renewal program in embryonic stem cells. Cell Stem Cell (2009) 2.09
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res (2009) 2.04
ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn (2012) 1.99
BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci U S A (2002) 1.89
Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol (2009) 1.84
Trends in treatment of advanced epithelial ovarian cancer in the Medicare population. Gynecol Oncol (2011) 1.77
Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol (2009) 1.77
Efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Am J Gastroenterol (2010) 1.75
Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol (2011) 1.74
Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol (2005) 1.72
Digital genomic quantification of tumor-infiltrating lymphocytes. Sci Transl Med (2013) 1.72
Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol (2002) 1.72
Plasma processing conditions substantially influence circulating microRNA biomarker levels. PLoS One (2013) 1.71
EMR for early gastric cancer in Korea: a multicenter retrospective study. Gastrointest Endosc (2007) 1.59
A feasibility study on the expanded indication for endoscopic submucosal dissection of early gastric cancer. Surg Endosc (2010) 1.56
Efficacy and safety of endoscopic treatment for nonampullary sporadic duodenal adenomas. Dig Dis Sci (2013) 1.53
Gender-related differences in visceral perception in health and irritable bowel syndrome. J Gastroenterol Hepatol (2006) 1.53
Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer (2008) 1.53
Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol (2007) 1.49
Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study. Cancer (2011) 1.47
The clinical applications of a systems approach. PLoS Med (2006) 1.44
Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol (2006) 1.43
Biomarkers of progestin therapy resistance and endometrial hyperplasia progression. Am J Obstet Gynecol (2012) 1.43
An evaluation of cervical cancer in women age sixty and over. Gynecol Oncol (2008) 1.43
APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res (2013) 1.43
Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. Mol Cancer Res (2007) 1.40
[Microsatellite instability in gastric B-cell lymphoma]. Korean J Gastroenterol (2006) 1.39
Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am J Pathol (2011) 1.33
MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. Mol Cancer Res (2011) 1.33
Efficacy and tolerability of split-dose magnesium citrate: low-volume (2 liters) polyethylene glycol vs. single- or split-dose polyethylene glycol bowel preparation for morning colonoscopy. Am J Gastroenterol (2010) 1.32
The 14-3-3 protein FTT-2 regulates DAF-16 in Caenorhabditis elegans. Dev Biol (2006) 1.27
Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. J Natl Compr Canc Netw (2009) 1.25
Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol (2012) 1.24
Healing rate of EMR-induced ulcer in relation to the duration of treatment with omeprazole. Gastrointest Endosc (2004) 1.23
Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS One (2013) 1.23
Clinical diagnosis of primary epiploic appendagitis: differentiation from acute diverticulitis. J Clin Gastroenterol (2002) 1.17
Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol (2008) 1.15
BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer (2012) 1.14
Prevalence and risk factors of Barrett's esophagus in Korea. J Gastroenterol Hepatol (2007) 1.13
Follow-up of in situ and early-stage fallopian tube carcinoma in patients undergoing prophylactic surgery for proven or suspected BRCA-1 or BRCA-2 mutations. Am J Surg Pathol (2004) 1.13
Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer (2009) 1.12
Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol (2006) 1.12
Glomus tumor of the stomach: a clinicopathologic analysis of 10 cases and review of the literature. Gut Liver (2012) 1.12
Vignette-based study of ovarian cancer screening: do U.S. physicians report adhering to evidence-based recommendations? Ann Intern Med (2012) 1.12
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc Natl Acad Sci U S A (2013) 1.11
Self-assessment of resident surgical skills: is it feasible? Am J Obstet Gynecol (2005) 1.11
Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci (2008) 1.11
Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer (2011) 1.11
An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription. Nucleic Acids Res (2011) 1.08